Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials

Ziba Majidi, Shaghayegh Hosseinkhani, Nasrin Amiri-Dashatan, Solaleh Emamgholipour, Sara Tutunchi, Javad Hashemi, Fatemeh Ghorbani, Mehdi Koushki
DOI: 10.1136/jim-2020-001588 Published 4 March 2021
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

No eLetters have been published for this article.
Back to top
Email
Print
Alerts
Citation Tools
Cite This
Download PDF

Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials
Ziba Majidi, Shaghayegh Hosseinkhani, Nasrin Amiri-Dashatan, Solaleh Emamgholipour, Sara Tutunchi, Javad Hashemi, Fatemeh Ghorbani, Mehdi Koushki
Journal of Investigative Medicine Mar 2021, 69 (3) 697-703; DOI: 10.1136/jim-2020-001588
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article